Daily News Podcast

Esketamine gets the green light for depression

Publish date: March 7, 2019

 

The FDA approves intranasal esketamine for refractory major depressive disorder. A behavioral intervention improves physical activity in patients with diabetes. Groups of physicians produce more accurate diagnoses than individuals. And there’s a new target for reducing sodium consumption.
Amazon Alexa
Apple Podcasts
Google Podcasts
Spotify

Recommended Reading

What I learned from Navy SEALs about resilience
MDedge Family Medicine
Mediterranean diet cut Parkinson’s risk
MDedge Family Medicine
A prescription for medicine’s gender inequality
MDedge Family Medicine
Parental leave inequities: Kirti Magudia and Thomas Ng, Part I
MDedge Family Medicine
Trump targets abortion by denying family planning funds
MDedge Family Medicine
Online vitriol’s expansion into doctor discussion sites
MDedge Family Medicine
Will having fewer primary care physicians shorten Americans’ lifespans?
MDedge Family Medicine
Cancer-battling breath, Zombie Bambi, and hops as health food
MDedge Family Medicine
Patients who want to make you retire, and how to cope
MDedge Family Medicine
Infective endocarditis isn’t what it used to be
MDedge Family Medicine